Column

• There is no single “best” obesity medication.
• Contraindications, comorbidities, polypharmacy, administration route, insurance coverage, affordability and patient preferences all influence treatment success.

As obesity medications continue to transform care, selecting the right one requires more than meeting BMI criteria.

From choosing the most appropriate medication to managing adverse effects and monitoring long-term health outcomes, it is crucial for clinicians to take a comprehensive and individualized approach to treatment.

BMI tells us who qualifies for treatment. Biology tells us which treatment is most likely to succeed.

One of the biggest shifts in obesity medicine over the past decade is that we’ve stopped asking, “Does this patient qualify for medication?” and started asking, “What is driving this patient’s obesity?” It is a fundamentally different conversation.

When I evaluate a patient for obesity medication, I’m not just looking at BMI, I’m looking at the entire cardiometabolic picture. Obesity rarely exists in isolation. It’s often the common denominator linking type 2 diabetes, hypertension, metabolic dysfunction-associated steatotic liver disease (MASLD), obstructive sleep apnea, osteoarthritis, infertility and cardiovascular disease. Understanding which of these conditions is driving the patient’s overall health risk often influences medication selection as much as the weight itself.

A baseline isn’t a checklist. It’s the map we will use to tell whether the medication is actually working.

I think of baseline evaluation less as a box-checking exercise and more as establishing the patient’s starting terrain, so that 6 months from now, I know whether we’re moving in the right direction or just watching the scale move.

That means weight, blood pressure, heart rate and a metabolic panel, including glycemic status, renal function and lipids. It also means a real conversation about a patient’s eating patterns, sleep quality, mood, prior weight-loss attempts and what happened to them, as well as a full medication reconciliation, because so many of our patients arrive on five or six other prescriptions that can interact with what we’re about to start.

I screen specifically for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) before initiating incretin-based therapy, and I ask directly about pancreatitis, gallbladder disease and psychiatric history, because these aren’t rare exclusions. They show up more often than people expect.

The goal isn’t just ruling out contraindications; it’s understanding the whole patient well enough that if something changes along the way, you can know whether it’s the medication, the disease, or something else entirely.

This is where obesity medicine stops being a formula and starts being medicine.

There’s no single “best” obesity medication. We only have the best medication for the biology sitting in front of you.

Two patients with identical BMIs can have completely different underlying drivers — one who is insulin resistant with fatty liver disease, another with binge eating patterns and no metabolic disease at all. Treating them the same because their BMI matches is how you get mismatched outcomes.

Rather than asking, “Which medication causes the most weight loss?” I ask, “What problem am I trying to solve?”

Is obesity driving poorly controlled diabetes, MASLD, cardiovascular risk, obstructive sleep apnea, polycystic ovary syndrome or severe osteoarthritis? Or is weight gain primarily related to menopause, psychiatric medications, chronic stress or emotional eating? The answers often determine which therapeutic mechanism is most appropriate.

I also believe medication selection should look beyond efficacy. Contraindications, comorbidities, polypharmacy, route of administration, insurance coverage, affordability and patient preferences all influence long-term success. Medication only works if patients can realistically stay on it.

Then there’s the human side of the decision: needle aversion, cost, insurance coverage and what the patient is willing to sustain for years, not weeks. A perfectly matched medication that a patient can’t afford or won’t inject isn’t the safest choice.

At the end of the day, “safety” isn’t abstract; it’s specific to the person in the room.

The future of obesity medicine isn’t simply choosing more powerful medications; it’s matching the right therapy to the right patient at the right time. That’s precision obesity care.

The scale is one biomarker. It should never be the only biomarker.

Starting an obesity medication is the beginning of the journey, not the end. Early follow-up is critical because it gives us the chance to optimize treatment, builds confidence and prevents patients from discontinuing therapy over manageable adverse effects or unrealistic expectations.

I typically see patients within 4 weeks of initiation and at each dose escalation, then every 1 to 3 months once they reach a stable maintenance dose. These visits aren’t weight checks. They’re opportunities to reassess overall cardiometabolic health, review tolerability, reinforce nutrition and physical activity, and confirm we’re still moving toward the goals that mattered when treatment began.

Beyond weight and vital signs, I track glycemic control, blood pressure, hepatic markers (particularly in patients with MASLD renal function when appropriate), sleep quality, mobility, energy and quality of life. Many patients see meaningful improvement in these areas well before they hit their weight-loss goal. In patients with diabetes, I watch closely for hypoglycemia and often need to adjust insulin or sulfonylurea doses as metabolic health improves.

The most overlooked part of follow-up is preserving lean muscle mass and nutritional status. As newer therapies drive greater weight loss, I ask routinely about protein intake, resistance exercise, fatigue and physical function, especially in older adults, where preventing sarcopenia and maintaining independence matter as much as the number on the scale.

Success isn’t defined by how much weight a patient loses. It’s defined by how much health they gain.

Setting expectations before the first dose is one of the most important parts of obesity care. Patients rarely stop treatment because of nausea. They stop because nobody prepared them for the journey.

When patients know that GI symptoms — nausea, early satiety, constipation and bloating — are common during dose escalation and usually temporary, they’re far less likely to read them as treatment failure. I lean on slower titration when needed, smaller protein-rich meals, adequate hydration and staying ahead of constipation rather than reacting to it. There’s no prize for reaching the top dose quickly.

As these therapies get more effective, though, the conversation must extend beyond GI symptoms. Rapid weight loss is its own safety issue if it isn’t paired with adequate nutrition. Muscle preservation, the sarcopenia risk I mentioned earlier, applies just as much here. In adolescents and young adults, significant appetite suppression can threaten adequate nutrition during a period where healthy growth still matters. These medications suppress appetite, not nutritional requirements.

Fatigue is another symptom that gets missed. Patients and clinicians often attribute it to low testosterone, menopause or thyroid disease when it’s frequently the result of reduced caloric intake, dehydration, inadequate protein or muscle loss from rapid weight change. Before ordering a workup, I reassess nutrition, hydration, activity and muscle-preserving strategies first.

The goal isn’t just weight loss — it’s fat loss with muscle, nutrition and function preserved. That’s what successful treatment looks like.

The obesity medication is rarely the only medication I worry about. It’s the entire medication ecosystem.

Most patients starting obesity medication aren’t on just one medication. They’re managing diabetes, hypertension, cardiovascular disease, depression, chronic pain or MASLD, often with complex regimens. Every new prescription should start with a full medication review.

A few interactions matter most. Insulin and sulfonylureas often need proactive dose reduction to avoid hypoglycemia as appetite and glycemic control improve. Naltrexone-containing therapies should be avoided with chronic opioid use, and bupropion-containing agents need caution in seizure disorders or uncontrolled hypertension. I also review serotonergic and sympathomimetic medications and monoamine oxidase inhibitors closely before starting any centrally acting therapy.

Delayed gastric emptying from incretin-based therapies is another factor. Clinically significant interactions are uncommon, but narrow-therapeutic-index drugs like warfarin or levothyroxine warrant closer monitoring, especially during dose escalation.

The most overlooked interaction, though, isn’t between medications; it’s between medications and nutrition. As appetite drops, patients can unintentionally cut protein and overall nutritional quality along with their intake. I reassess diet, hydration and medication need together, because effective obesity treatment often means deprescribing diabetes, hypertension and other cardiometabolic medications, not adding to them.

One of the most rewarding parts of this work is that effective treatment often simplifies the regimen. Sometimes the best drug interaction is the one that disappears because the patient no longer needs a medication.

One of the biggest misconceptions in obesity care is that if a patient doesn’t respond to the first medication, they’ve somehow failed treatment. We’d never say that about hypertension or diabetes, yet patients with obesity often internalize that message.

Obesity is a heterogeneous disease. Not every medication works equally well for every individual. In obesity medicine, changing the treatment plan is not a sign of failure; it’s good clinical medicine.

If a patient hasn’t achieved meaningful clinical benefit after roughly 3 months at the maximally tolerated dose, I reassess the whole picture before changing course adherence: sleep, nutrition, activity, psychosocial stressors, administration technique and whether we picked the right mechanism for that patient’s biology in the first place. Sometimes optimizing those factors is enough. Other times, switching mechanisms is the right move.

On the safety side, persistent intolerable GI symptoms despite slower titration, pancreatitis, severe hypersensitivity, worsening psychiatric symptoms or other medication-specific contraindications warrant stopping or switching therapy.

The goal was never to keep a patient on one medication forever; it’s to find what safely improves their long-term health. Knowing when to pivot is part of the job, not a departure from it.

The biggest barrier to long-term success usually isn’t the medication, it’s expectations. So, the first prescription I write isn’t for medication. It’s for understanding obesity as a chronic disease.

Many patients still see obesity medication as a short-term fix or expect weight loss to be linear. Neither matches biology.

I explain that these medications treat dysregulated appetite, satiety and energy homeostasis; they’re not a replacement for willpower. Patients who understand that biology stay more engaged, and they’re less likely to blame themselves if progress slows or weight returns after stopping treatment.

I also encourage patients to redefine success early. Weight loss matters, but glycemic control, liver health, cardiovascular risk, mobility, sleep, joint pain and quality of life are just as meaningful. Plateaus are part of every chronic disease course; they don’t mean the medication has stopped working.

The message I come back to most: obesity is a chronic disease, not a character flaw. Weight regain reflects the disease’s biology, not a lack of effort. That one conversation does more for stigma, adherence and trust than almost anything else I say.

The future of obesity medicine isn’t just better medications; it’s smarter, more personalized care.

Newer oral incretins, dual agonists and multi-agonist therapies keep expanding our options, but I think the next real advance is precision obesity medicine — matching treatment to a patient’s biology, comorbidities and goals rather than BMI alone.

As these therapies become more effective, preserving lean muscle mass and physical function will become an increasingly important measure of high-quality obesity care. Integrating nutrition and resistance training into routine treatment should be essential rather than an afterthought.

I also think obesity medicine is becoming cardiometabolic medicine, full stop. Success will be measured less in pounds and more in cardiovascular risk reduction, MASLD improvement, diabetes remission, kidney protection, mobility and quality of life.

This isn’t about who can help patients lose the most weight anymore. It’s about who can get patients healthier and keep them that way.

As our therapies become more powerful, our monitoring has to become more meaningful — tracking not just how much weight comes off, but how it comes off. Body composition and physical function, not just the scale, need to become standard parts of follow-up, especially in older adults and adolescents, for the reasons I mentioned earlier.

The bigger shift I expect is in what gets measured as a marker of success in the first place. Right now, most monitoring frameworks are still built around weight and glycemic control. I think we’ll see formal monitoring protocols start to routinely incorporate cardiovascular risk markers, MASLD improvement, kidney function, sleep and mobility as core outcomes, not secondary ones, alongside the deprescribing conversation I mentioned earlier, which will need its own structured follow-up as more patients qualify for it.

We’re moving from monitoring that asks, “How much weight did they lose?” to monitoring that asks, “How much healthier are they?” That shift is overdue, and the newer therapies are finally forcing it.

If I had to point a colleague toward three places that would provide more education on obesity medications, the first would be the Obesity Medicine Association (OMA) Obesity Algorithm, which is the most practical, regularly updated reference for medication selection tied to comorbidities. The second would be the OMA Clinical Practice Statements, which go deeper on specific topics like GLP-1 receptor agonist use with real point-of-care applicability. Lastly, for clinicians who want structured education I would recommend OMA’s Obesity Medicine Certification and CME programming.

Shagun Bindlish, MD, FACP, FOMA, is an internist and diabetologist with advanced expertise in obesity and lifestyle medicine. She can be reached at primarycare@healio.com.